Super Vision Secures ￥52.2 Million in Series A Funding

(VCBeat) Aug. 06, 2021 -- Recently, Super Vision Technology (Beijing) Co., Ltd. ("Super Vision"), an eye disease therapy R&D platform, announced the successful completion of a ￥52.2 million Series A round of financing, with participation from Tsinghua Innovation Ventures, Founder Hecheng, Granary Capital, Dongsheng Technology Park Ruisheng Investment and Zhonghui Health Industry Co., Ltd. The funds raised will be used to consolidate Super Vision's research and development foundation, expand the product pipeline, further improve the production system, and prepare for clinical trials of products.

Super Vision was founded by Professor Wang Lejin, chief physician of Peking University People's Hospital, chief scientist of major instrument project of National Natural Science Foundation of China, and a leading ophthalmologist. Super Vision is dedicated to the scientific and technological innovation of eye disease therapy. Currently, the company has developed four product lines covering the treatment needs of mainstream eye diseases such as myopia, glaucoma, and pediatric ophthalmology.

On July 31, 2021, the opening ceremony of Super Vision's GMP production base was held in Beijing. Lasted five months, the base was officially completed and put into operation.

Wang Tianfang, CEO of Super Vision, said, " the completion of the base means Super Vision accomplished the transformation from research to production, also means Super Vision fully independently has the mass production capacity of Class III active implantable medical devices with the most strict supervision, the most difficult process and the highest technical level. It is of great significance for Super Vision."

Tsinghua Innovation Ventures is a scientific achievement industrialization investment management company under the Beijing Tsinghua Industrial Development Research Institute. It is committed to promoting the commercialization of Tsinghua University's major scientific and technological achievements. The company has invested more than 60 projects in total.

Founder H Fund, a wholly-owned subsidiary of Founder Securities Co. Ltd., is a professional financial investment management institution that has been committed to providing direct investment services. It is approved by the China Securities Regulatory Commission, and ranks among the Top 10 PE Subsidized by Securities Companies in China. The core team has more than 10 years of experience in equity investments, mergers and acquisitions, cross-border investments, and mezzanine investments in the capital market.